[DOI] [PubMed] [Google Scholar] 111
Patients and trial participants should be aware of the following red flag symptoms that require urgent review: Dysphagia (difficulty swallowing) or odynophagia (painful swallowing) Unexplained weight loss beyond that expected from the medication Persistent vomiting or an inability to keep fluids down Haematemesis (vomiting blood) or melaena (black, tarry stools) Severe or worsening chest pain if you experience severe chest pain, particularly with breathlessness, sweating, or pain radiating to the arm or jaw, call 999 immediately , as these may indicate a cardiac emergency rather than a digestive cause Symptoms that persist despite appropriate self-management , or that significantly affect daily life These symptoms may indicate more serious conditions such as oesophagitis, peptic ulceration, or, in rare cases, upper GI pathology requiring endoscopic investigation
While there is no direct interaction between them, monitoring how your body responds and following dosing guidelines can help prevent unwanted side effects
Research suggests that GLP-1 receptor agonists may reduce the hedonic or pleasure-driven aspects of eating, potentially making high-calorie, palatable foods less appealing
We observed that FSP1 expression levels correlated with changes in PPARa
doi: 10.1111/jgh.13278 178
